BERLIN and SEATTLE, Aug. 2, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported financial results for the second quarter/ first half of 2007, which ended June 30, 2007.
